No Detail Found!

Regulation of stability studies to enhance the efficiency of drug registrations to regulatory authorities

Author(s)
Mohammad Sajjad Khan Drug, Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Nabila Akhtar Drug, Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Abstract
Stability testing is an important tool to assess the quality of drug substances and products which may vary with time under influence of variety of factors such as temperature, humidity, and light. Stability studies of drugs are designed according to the climatic zones to establish a retest period for active drug substance or a shelf life for the finished product as well as to recommend the storage conditions. The strict regulatory requirements on designing, performing evaluating stability study to claim the expiry date, and shelf life of drug products are based on a series of regulatory requirements and advisory guidelines that have been developed by regulatory authorities of US, Europe, and Japan which; were harmonized through the development of the International Conference on Harmonization (ICH) procedures. To assess the stability of drug substances and products, the design and conduct of stability studies, defining relevant thresholds for impurities testing is required with a current good manufacturing practice-based risk management approach to achieve a robust stability of pharmaceutical dosage forms. There are relevant requirements that cover new drug substances and products as well as new dosage forms containing existing active ingredients and vice versa.
Publication Details
Page(s) 48-58
Published Journal: Archives of Pharmacy Practice, Volume: 6, Issue: 3, Year: 2015

Request the full text from PASTIC

Keywords
international conference on harmonization ICH, Climatic zones, regulatory, stability of drugs
References
Kommanaboyina B,Rhodes CT .1999 .Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm, 25 : 857-68.
Banker GS,Dekker M .1996 .Modern pharmaceutics. , : .
.2003 .Stability Data Package for Registration Applications in Climatic Zones III and IV, EMEA (The European Agency for the Evaluation of Medicinal Products). , : 1-5.
Dietz R,Feilner K,Gerst F,Grimm W. .1993 .Drug stability Testing‑Classification of countries according to climatic zones. Drugs Made Ger, 36 : 99-103.
.2003 .Stability testing of new drug substances and products. , : 1-20.
.1996 .Stability testing of new dosage forms, in Q1C, I.c. Maryland: Food and Drug Administration, : 1-3.
.1998 .Photostability testing of new active substances and medicinal products in Q1B, EMEA (European medicines agency). , : 1-20.
EMEA .2001 .(European medicines agency). , : 1-2.
EMEA .2003 .(European medicines agency). , : 1-18.
EMEA .2003 .(European medicines agency). , : 1-17.
Administration Drug .1999 .Specifications: Test procedured and acceptance criteria for new drug substances and new drug products, in Q6A. ICH (International conference on harmonization), : 1-35.
Administration Drug .2003 .Impurities in new drug products, in Q3B. ICH (International Conference on Harmonization), : 1-16.
EMEA .2002 .Bracketing and matrixing designs for stability testing of drug substances and drug products. medicines agency), : 1-8.
Ruberg SJ,Stegeman JW .1991 .Pooling data for stability studeis: Testing the equality of batch degradation slopes. Biometrics, 47 : 1059-69.
Fairweather WR,Lin TY,Kelly R .1995 .Regulatory design and analysis aspects of complex stability studies. US Food and Drug Administration. J Pharm Sci, 84 : 1322-6.
.1998 .Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV. Drug Dev Ind Pharm, 24 : 313-25.
Chen JJ . .Shelf life estimation for multifactor stability. , : .
0

Citations

0

Downloads

6

Views